首页 > 最新文献

Annals of Clinical and Translational Neurology最新文献

英文 中文
No replicating evidence for anti-amyloid-β autoantibodies in cerebral amyloid angiopathy-related inflammation 脑淀粉样血管病相关炎症中抗淀粉样蛋白-β自身抗体无重复证据
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-13 DOI: 10.1002/acn3.52169
Emma van den Berg, Rian Roelofs, Lieke Jäkel, Steven M. Greenberg, Andreas Charidimou, Ellis S. van Etten, Delphine Boche, Catharina J. M. Klijn, Floris H. B. M. Schreuder, H. Bea Kuiperij, Marcel M. Verbeek

Objective

Elevated levels of anti-amyloid-β (anti-Aβ) autoantibodies in cerebrospinal fluid (CSF) have been proposed as a diagnostic biomarker for cerebral amyloid angiopathy-related inflammation (CAA-RI). We aimed to independently validate the immunoassay for quantifying these antibodies and evaluate its diagnostic value for CAA-RI.

Methods

We replicated the immunoassay to detect CSF anti-Aβ autoantibodies using CSF from CAA-RI patients and non-CAA controls with unrelated disorders and further characterized its performance. Moreover, we conducted a literature review of CAA-RI case reports to investigate neuropathological and CSF evidence of the nature of the inflammatory reaction in CAA-RI.

Results

The assay demonstrated a high background signal in CSF, which increased and corresponded with higher total immunoglobulin G (IgG) concentration in CSF (rsp = 0.51, p = 0.02). Assay levels were not elevated in CAA-RI patients (n = 6) compared to non-CAA controls (n = 20; p = 0.64). Literature review indicated only occasional presence of B-lymphocytes and plasma cells (i.e., antibody-producing cells), alongside the abundant presence of activated microglial cells, T-cells, and other monocyte lineage cells. CSF analysis did not convincingly indicate intrathecal IgG production.

Interpretation

We were unable to reproduce the reported elevation of anti-Aβ autoantibody concentration in CSF of CAA-RI patients. Our findings instead support nonspecific detection of IgG levels in CSF by the assay. Reviewed CAA-RI case reports suggested a widespread cerebral inflammatory reaction. In conclusion, our findings do not support anti-Aβ autoantibodies as a diagnostic biomarker for CAA-RI.

目的脑脊液(CSF)中抗淀粉样蛋白-β(anti-Aβ)自身抗体水平的升高被认为是脑淀粉样血管病相关炎症(CAA-RI)的诊断生物标志物。方法我们使用CAA-RI患者和非CAA对照组的脑脊液复制了检测CSF抗Aβ自身抗体的免疫测定法,并进一步鉴定了其性能。此外,我们还对 CAA-RI 病例报告进行了文献回顾,以调查神经病理学和 CSF 中有关 CAA-RI 炎症反应性质的证据。结果该检测方法在 CSF 中显示出较高的背景信号,随着 CSF 中总免疫球蛋白 G (IgG) 浓度的升高,背景信号也随之升高(rsp = 0.51,p = 0.02)。与非 CAA 对照组(n = 20;p = 0.64)相比,CAA-RI 患者(n = 6)的检测水平没有升高。文献综述显示,除了大量存在活化的小胶质细胞、T 细胞和其他单核细胞系细胞外,B 淋巴细胞和浆细胞(即抗体产生细胞)只是偶尔存在。CSF分析并不能令人信服地表明鞘内IgG的产生。我们的研究结果反而支持用该检测方法非特异性地检测 CSF 中的 IgG 水平。经审查的 CAA-RI 病例报告表明,脑部炎症反应广泛存在。总之,我们的研究结果不支持将抗Aβ自身抗体作为CAA-RI的诊断生物标志物。
{"title":"No replicating evidence for anti-amyloid-β autoantibodies in cerebral amyloid angiopathy-related inflammation","authors":"Emma van den Berg,&nbsp;Rian Roelofs,&nbsp;Lieke Jäkel,&nbsp;Steven M. Greenberg,&nbsp;Andreas Charidimou,&nbsp;Ellis S. van Etten,&nbsp;Delphine Boche,&nbsp;Catharina J. M. Klijn,&nbsp;Floris H. B. M. Schreuder,&nbsp;H. Bea Kuiperij,&nbsp;Marcel M. Verbeek","doi":"10.1002/acn3.52169","DOIUrl":"10.1002/acn3.52169","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Elevated levels of anti-amyloid-β (anti-Aβ) autoantibodies in cerebrospinal fluid (CSF) have been proposed as a diagnostic biomarker for cerebral amyloid angiopathy-related inflammation (CAA-RI). We aimed to independently validate the immunoassay for quantifying these antibodies and evaluate its diagnostic value for CAA-RI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We replicated the immunoassay to detect CSF anti-Aβ autoantibodies using CSF from CAA-RI patients and non-CAA controls with unrelated disorders and further characterized its performance. Moreover, we conducted a literature review of CAA-RI case reports to investigate neuropathological and CSF evidence of the nature of the inflammatory reaction in CAA-RI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The assay demonstrated a high background signal in CSF, which increased and corresponded with higher total immunoglobulin G (IgG) concentration in CSF (<i>r</i><sub>sp</sub> = 0.51, <i>p</i> = 0.02). Assay levels were not elevated in CAA-RI patients (<i>n</i> = 6) compared to non-CAA controls (<i>n</i> = 20; <i>p</i> = 0.64). Literature review indicated only occasional presence of B-lymphocytes and plasma cells (i.e., antibody-producing cells), alongside the abundant presence of activated microglial cells, T-cells, and other monocyte lineage cells. CSF analysis did not convincingly indicate intrathecal IgG production.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>We were unable to reproduce the reported elevation of anti-Aβ autoantibody concentration in CSF of CAA-RI patients. Our findings instead support nonspecific detection of IgG levels in CSF by the assay. Reviewed CAA-RI case reports suggested a widespread cerebral inflammatory reaction. In conclusion, our findings do not support anti-Aβ autoantibodies as a diagnostic biomarker for CAA-RI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endogenous tPA levels: A biomarker for discriminating hemorrhagic stroke from ischemic stroke and stroke mimics 内源性 tPA 水平:区分出血性中风与缺血性中风和中风模拟物的生物标志物
IF 5.3 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-11 DOI: 10.1002/acn3.52197
Melissa Jauquet, Pierre Gagnepain, Estelle La Porte, Audrey M. Thiebaut, Ambre Rochey, Helene Legros, Baptiste Laine, Marion Berthelot, Valerie Roussel, Joan Montaner, Barbara Casolla, Denis Vivien, Eloise Lemarchand, Richard Macrez, Benoit D. Roussel
ObjectiveStroke is the leading cause of death and disability. Timely differentiation between ischemic stroke, hemorrhagic stroke, and stroke mimics is critical for tailored treatment and triage. To accelerate the identification of stroke's subtype, we propose to use the levels of circulating tPA as a biomarker.MethodsBiostroke is an observational study performed at the Caen Hospital. We quantified tPA levels in 110 patients with ischemic strokes, 30 patients with hemorrhagic strokes, and 67 stroke mimic patients upon their arrival at the emergency. Two logistic regression models were formulated: one with parameters measurable in an ambulance (Model A) and one with parameters measurable at the hospital (Model H). These models were both tested with or without plasma tPA measurements. Our initial assessment involved evaluating the effectiveness of both models in distinguishing between hemorrhagic strokes, ischemic strokes, and stroke mimics within our study cohort.ResultsPlasmatic tPA levels exhibit significant distinctions between hemorrhagic, ischemic, and mimic stroke patients (1.8; 2.5; 2.4 ng/mL, respectively). The inclusion of tPA in model A significantly enhances the classification accuracy of hemorrhagic patients only, increasing identification from 0.67 (95% CI, 0.59 to 0.75) to 0.78 (95% CI, 0.7 to 0.85) (p = 0.0098). Similarly, in model H, classification accuracy of hemorrhagic patients significantly increased with the addition of tPA, rising from 0.75 (95% CI, 0.67 to 0.83) without tPA to 0.86 (95% CI, 0.81 to 0.91) with tPA (p = 0.024).InterpretationsOur findings underscore the valuable role of tPA levels in distinguishing between stroke subtypes.
目的中风是导致死亡和残疾的主要原因。及时区分缺血性脑卒中、出血性脑卒中和脑卒中模拟症对于进行有针对性的治疗和分流至关重要。为了加快对中风亚型的识别,我们建议使用循环中 tPA 的水平作为生物标志物。我们对 110 名缺血性脑卒中患者、30 名出血性脑卒中患者和 67 名模拟脑卒中患者在到达急诊室时的 tPA 水平进行了量化。我们建立了两个逻辑回归模型:一个是在救护车上测量的参数模型(模型 A),另一个是在医院测量的参数模型(模型 H)。这些模型都在有或没有血浆 tPA 测量值的情况下进行了测试。我们的初步评估包括评价这两种模型在我们的研究队列中区分出血性中风、缺血性中风和中风模拟者的有效性。结果血浆 tPA 水平在出血性、缺血性和模拟中风患者之间表现出显著的区别(分别为 1.8;2.5;2.4 纳克/毫升)。在模型 A 中加入 tPA 可显著提高出血性患者的分类准确性,识别率从 0.67(95% CI,0.59 至 0.75)提高到 0.78(95% CI,0.7 至 0.85)(p = 0.0098)。同样,在模型 H 中,加入 tPA 后出血性患者的分类准确率显著提高,从未加 tPA 时的 0.75(95% CI,0.67 至 0.83)提高到加了 tPA 后的 0.86(95% CI,0.81 至 0.91)(p = 0.024)。
{"title":"Endogenous tPA levels: A biomarker for discriminating hemorrhagic stroke from ischemic stroke and stroke mimics","authors":"Melissa Jauquet, Pierre Gagnepain, Estelle La Porte, Audrey M. Thiebaut, Ambre Rochey, Helene Legros, Baptiste Laine, Marion Berthelot, Valerie Roussel, Joan Montaner, Barbara Casolla, Denis Vivien, Eloise Lemarchand, Richard Macrez, Benoit D. Roussel","doi":"10.1002/acn3.52197","DOIUrl":"https://doi.org/10.1002/acn3.52197","url":null,"abstract":"ObjectiveStroke is the leading cause of death and disability. Timely differentiation between ischemic stroke, hemorrhagic stroke, and stroke mimics is critical for tailored treatment and triage. To accelerate the identification of stroke's subtype, we propose to use the levels of circulating tPA as a biomarker.MethodsBiostroke is an observational study performed at the Caen Hospital. We quantified tPA levels in 110 patients with ischemic strokes, 30 patients with hemorrhagic strokes, and 67 stroke mimic patients upon their arrival at the emergency. Two logistic regression models were formulated: one with parameters measurable in an ambulance (Model A) and one with parameters measurable at the hospital (Model H). These models were both tested with or without plasma tPA measurements. Our initial assessment involved evaluating the effectiveness of both models in distinguishing between hemorrhagic strokes, ischemic strokes, and stroke mimics within our study cohort.ResultsPlasmatic tPA levels exhibit significant distinctions between hemorrhagic, ischemic, and mimic stroke patients (1.8; 2.5; 2.4 ng/mL, respectively). The inclusion of tPA in model A significantly enhances the classification accuracy of hemorrhagic patients only, increasing identification from 0.67 (95% CI, 0.59 to 0.75) to 0.78 (95% CI, 0.7 to 0.85) (<jats:italic>p</jats:italic> = 0.0098). Similarly, in model H, classification accuracy of hemorrhagic patients significantly increased with the addition of tPA, rising from 0.75 (95% CI, 0.67 to 0.83) without tPA to 0.86 (95% CI, 0.81 to 0.91) with tPA (<jats:italic>p</jats:italic> = 0.024).InterpretationsOur findings underscore the valuable role of tPA levels in distinguishing between stroke subtypes.","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tractography of sensorimotor pathways in dyskinetic cerebral palsy: Association with motor function 运动障碍型脑瘫患者的感觉运动通路分枝图:与运动功能的关系
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-10 DOI: 10.1002/acn3.52174
Xavier Caldú, Lee B. Reid, Kerstin Pannek, Jurgen Fripp, Júlia Ballester-Plané, David Leiva, Roslyn N. Boyd, Roser Pueyo, Olga Laporta-Hoyos

Objectives

Neuroimaging studies of dyskinetic cerebral palsy (CP) are scarce and the neuropathological underpinnings are not fully understood. We delineated the corticospinal tract (CST) and cortico-striatal-thalamocortical (CSTC) pathways with probabilistic tractography to assess their (1) integrity and (2) association with motor functioning in people with dyskinetic CP.

Methods

Diffusion weighted magnetic resonance images were obtained for 33 individuals with dyskinetic CP and 33 controls. Fractional anisotropy (FA) and mean diffusivity (MD) for the CST and the CSTC pathways were compared between groups. Correlation analyses were performed between tensor metric values and motor function scores of participants with dyskinetic CP as assessed by the Gross Motor Function Classification System (GMFCS), the Bimanual Fine Motor Function (BFMF), and the Manual Ability Classification System (MACS).

Results

White matter integrity in both the CST and the CSTC pathways was reduced in people with dyskinetic CP. The GMFCS, MACS and, less commonly, the BFMF were associated with FA and, particularly, MD in most portions of these pathways.

Interpretation

The present study advances our understanding of the involvement of white matter microstructure in sensorimotor pathways and its relationship with motor impairment in people with dyskinetic CP. Our results are consistent with well-described relationships between upper limb function and white matter integrity in the CST and CSTC pathways in other forms of CP. This knowledge may ultimately help prognosis and therapeutic programmes.

目的运动障碍型脑瘫(CP)的神经影像学研究很少,其神经病理学基础也不完全清楚。我们采用概率性束图对皮质脊髓束(CST)和皮质-纹状体-脑皮质(CSTC)通路进行了划分,以评估它们(1)的完整性和(2)与运动功能障碍患者的关联。比较各组间 CST 和 CSTC 通路的分数各向异性(FA)和平均扩散率(MD)。通过粗大运动功能分类系统 (GMFCS)、双臂精细运动功能 (BFMF) 和手动能力分类系统 (MACS),对张量指标值和运动功能评分进行了相关性分析。本研究加深了我们对感觉运动通路中白质微结构的参与及其与运动障碍 CP 患者运动障碍之间关系的理解。我们的研究结果与其他形式的 CP 中上肢功能与 CST 和 CSTC 通路白质完整性之间的关系描述一致。这些知识最终可能有助于预后和治疗方案。
{"title":"Tractography of sensorimotor pathways in dyskinetic cerebral palsy: Association with motor function","authors":"Xavier Caldú,&nbsp;Lee B. Reid,&nbsp;Kerstin Pannek,&nbsp;Jurgen Fripp,&nbsp;Júlia Ballester-Plané,&nbsp;David Leiva,&nbsp;Roslyn N. Boyd,&nbsp;Roser Pueyo,&nbsp;Olga Laporta-Hoyos","doi":"10.1002/acn3.52174","DOIUrl":"10.1002/acn3.52174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Neuroimaging studies of dyskinetic cerebral palsy (CP) are scarce and the neuropathological underpinnings are not fully understood. We delineated the corticospinal tract (CST) and cortico-striatal-thalamocortical (CSTC) pathways with probabilistic tractography to assess their (1) integrity and (2) association with motor functioning in people with dyskinetic CP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Diffusion weighted magnetic resonance images were obtained for 33 individuals with dyskinetic CP and 33 controls. Fractional anisotropy (FA) and mean diffusivity (MD) for the CST and the CSTC pathways were compared between groups. Correlation analyses were performed between tensor metric values and motor function scores of participants with dyskinetic CP as assessed by the Gross Motor Function Classification System (GMFCS), the Bimanual Fine Motor Function (BFMF), and the Manual Ability Classification System (MACS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>White matter integrity in both the CST and the CSTC pathways was reduced in people with dyskinetic CP. The GMFCS, MACS and, less commonly, the BFMF were associated with FA and, particularly, MD in most portions of these pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The present study advances our understanding of the involvement of white matter microstructure in sensorimotor pathways and its relationship with motor impairment in people with dyskinetic CP. Our results are consistent with well-described relationships between upper limb function and white matter integrity in the CST and CSTC pathways in other forms of CP. This knowledge may ultimately help prognosis and therapeutic programmes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Muscular dystrophy patients show low exercise‐induced blood flow in muscles with normal strength 肌肉萎缩症患者在力量正常的肌肉中显示出低运动诱导血流量
IF 5.3 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-09 DOI: 10.1002/acn3.52194
Orna Gera, Efrat Shavit‐Stein, Taly Amichai, Joab Chapman, Odelia Chorin, Lior Greenbaum, Amir Dori
ObjectiveNeuromuscular evaluation increasingly employs muscle ultrasonography to determine muscle thickness, mean grayscale echointensity, and visual semiquantitative echotexture attenuation. However, these measures provide low sensitivity for detection of mild muscle abnormality. Exercise‐induced intramuscular blood flow is a physiologic phenomenon, which may be impaired in mildly affected muscles, particularly in dystrophinopathies, and may indicate functional muscle ischemia. We aimed to determine if muscle blood flow is reduced in patients with neuromuscular disorders and preserved muscle strength, and if it correlates with echointensity and digital echotexture measurements.MethodsPeak exercise‐induced blood flow, echointensity, and echotexture were quantified in the elbow flexor muscles of 15 adult patients with Becker muscular dystrophy (BMD) and 13 patients with other muscular dystrophies (OMD). These were compared to 17 patients with Charcot–Marie–Tooth type 1 (CMT1) neuropathy and 21 healthy adults from a previous study.ResultsMuscle blood flow was reduced in all patient groups compared to controls, most prominently in BMD patients (p < 0.0001). Echointensity was similarly increased in all patient groups (p < 0.05), while echotexture was reduced only in muscular dystrophy patients (p ≤ 0.002). In BMD, blood flow correlated with echotexture (Pearson r = 0.6098, p = 0.0158) and strength (Spearman r = 0.5471; p = 0.0370). In patients with normal muscle strength, reduced muscle blood flow was evident in all patient groups (p < 0.001), echotexture was reduced in BMD and OMD (p < 0.01), and echointensity was increased in CMT (p < 0.05).InterpretationMuscle blood flow is a sensitive measure to detect abnormality, even in muscles with normal strength. Increased echointensity may indicate a neurogenic disorder when strength is preserved, while low echotexture suggests a dystrophic disease.
目的神经肌肉评估越来越多地采用肌肉超声造影来确定肌肉厚度、平均灰度回声密度和可视半定量回声纹理衰减。然而,这些方法对检测轻微肌肉异常的灵敏度较低。运动引起的肌肉内血流是一种生理现象,在轻度受影响的肌肉(尤其是肌营养不良症)中可能会受损,并可能提示功能性肌肉缺血。我们的目的是确定肌肉血流是否在神经肌肉疾病患者中减少,以及是否与回声点密度和数字回声纹理测量值相关。方法对 15 名贝克型肌营养不良症(BMD)成年患者和 13 名其他肌营养不良症(OMD)患者的肘屈肌运动诱导的峰值血流、回声点密度和回声纹理进行量化。结果与对照组相比,所有患者组的肌肉血流量都减少了,其中贝克尔肌营养不良症患者的减少最为明显(p <0.0001)。所有患者组的回声密度同样增加(p <0.05),而只有肌肉萎缩症患者的回声纹理减少(p ≤ 0.002)。在 BMD 中,血流与回声纹理(Pearson r = 0.6098,p = 0.0158)和肌力(Spearman r = 0.5471;p = 0.0370)相关。在肌力正常的患者中,所有患者组的肌肉血流量都明显减少(p <0.001),BMD 和 OMD 的回声纹理减少(p <0.01),CMT 的回声密度增加(p <0.05)。当肌肉力量保持正常时,回声密度增加可能预示着神经源性疾病,而低回声纹理则预示着肌肉萎缩性疾病。
{"title":"Muscular dystrophy patients show low exercise‐induced blood flow in muscles with normal strength","authors":"Orna Gera, Efrat Shavit‐Stein, Taly Amichai, Joab Chapman, Odelia Chorin, Lior Greenbaum, Amir Dori","doi":"10.1002/acn3.52194","DOIUrl":"https://doi.org/10.1002/acn3.52194","url":null,"abstract":"ObjectiveNeuromuscular evaluation increasingly employs muscle ultrasonography to determine muscle thickness, mean grayscale echointensity, and visual semiquantitative echotexture attenuation. However, these measures provide low sensitivity for detection of mild muscle abnormality. Exercise‐induced intramuscular blood flow is a physiologic phenomenon, which may be impaired in mildly affected muscles, particularly in dystrophinopathies, and may indicate functional muscle ischemia. We aimed to determine if muscle blood flow is reduced in patients with neuromuscular disorders and preserved muscle strength, and if it correlates with echointensity and digital echotexture measurements.MethodsPeak exercise‐induced blood flow, echointensity, and echotexture were quantified in the elbow flexor muscles of 15 adult patients with Becker muscular dystrophy (BMD) and 13 patients with other muscular dystrophies (OMD). These were compared to 17 patients with Charcot–Marie–Tooth type 1 (CMT1) neuropathy and 21 healthy adults from a previous study.ResultsMuscle blood flow was reduced in all patient groups compared to controls, most prominently in BMD patients (<jats:italic>p</jats:italic> &lt; 0.0001). Echointensity was similarly increased in all patient groups (<jats:italic>p</jats:italic> &lt; 0.05), while echotexture was reduced only in muscular dystrophy patients (p ≤ 0.002). In BMD, blood flow correlated with echotexture (Pearson <jats:italic>r</jats:italic> = 0.6098, <jats:italic>p</jats:italic> = 0.0158) and strength (Spearman <jats:italic>r</jats:italic> = 0.5471; <jats:italic>p</jats:italic> = 0.0370). In patients with normal muscle strength, reduced muscle blood flow was evident in all patient groups (<jats:italic>p</jats:italic> &lt; 0.001), echotexture was reduced in BMD and OMD (<jats:italic>p</jats:italic> &lt; 0.01), and echointensity was increased in CMT (<jats:italic>p</jats:italic> &lt; 0.05).InterpretationMuscle blood flow is a sensitive measure to detect abnormality, even in muscles with normal strength. Increased echointensity may indicate a neurogenic disorder when strength is preserved, while low echotexture suggests a dystrophic disease.","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Juvenile-onset Huntington's disease – Spectrum and evolution of presenting movement disorders 少年型亨廷顿氏病--运动障碍的谱系和演变。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-06 DOI: 10.1002/acn3.52193
Kathryn Yang, Vicente Quiroz, Amy Tam, Rasha Srouji, Ximena Villanueva, Claudia Amarales, Darius Ebrahimi-Fakhari

Juvenile-onset Huntington's disease (HD) is a rare subset of HD with symptom-onset before the age of 18. In contrast to the adult population, children present early-on with behavioral, psychiatric, and cognitive symptoms, in addition to a diverse spectrum of movement disorders. This poses a distinct challenge in diagnosis and management. We here describe the spectrum of movement disorders, accompanied with detailed video recordings, in seven cases of juvenile-onset HD. Our findings highlight early cognitive and behavioral symptoms, preceding motor symptoms. The diverse movement disorder phenotypes included dystonia, Parkinsonism, myoclonus, and chorea, findings which underscore the heterogeneity of presenting symptoms.

青少年型亨廷顿氏病(HD)是一种罕见的亚型亨廷顿氏病,症状在18岁之前出现。与成人不同的是,儿童在发病初期会出现行为、精神和认知症状,此外还伴有各种运动障碍。这给诊断和管理带来了独特的挑战。我们在此通过详细的视频记录,描述了七例青少年型 HD 患者的运动障碍谱。我们的发现突出了运动症状之前的早期认知和行为症状。运动障碍的表型多种多样,包括肌张力障碍、帕金森氏症、肌阵挛和舞蹈症,这些发现强调了表现症状的异质性。
{"title":"Juvenile-onset Huntington's disease – Spectrum and evolution of presenting movement disorders","authors":"Kathryn Yang,&nbsp;Vicente Quiroz,&nbsp;Amy Tam,&nbsp;Rasha Srouji,&nbsp;Ximena Villanueva,&nbsp;Claudia Amarales,&nbsp;Darius Ebrahimi-Fakhari","doi":"10.1002/acn3.52193","DOIUrl":"10.1002/acn3.52193","url":null,"abstract":"<p>Juvenile-onset Huntington's disease (HD) is a rare subset of HD with symptom-onset before the age of 18. In contrast to the adult population, children present early-on with behavioral, psychiatric, and cognitive symptoms, in addition to a diverse spectrum of movement disorders. This poses a distinct challenge in diagnosis and management. We here describe the spectrum of movement disorders, accompanied with detailed video recordings, in seven cases of juvenile-onset HD. Our findings highlight early cognitive and behavioral symptoms, preceding motor symptoms. The diverse movement disorder phenotypes included dystonia, Parkinsonism, myoclonus, and chorea, findings which underscore the heterogeneity of presenting symptoms.</p>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52193","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative technology-based interventions in Parkinson's disease: A systematic review and meta-analysis 帕金森病的创新技术干预:系统回顾和荟萃分析。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-05 DOI: 10.1002/acn3.52160
Chun En Yau, Eric Chi Kiat Ho, Natasha Yixuan Ong, Clifton Joon Keong Loh, Aaron Shengting Mai, Eng-King Tan

Objective

Novel technology-based interventions have the potential to improve motor symptoms and gait in Parkinson's disease (PD). Promising treatments include virtual-reality (VR) training, robotic assistance, and biofeedback. Their effectiveness remains unclear, and thus, we conducted a Bayesian network meta-analysis.

Methods

We searched the Medline, Embase, Cochrane CENTRAL, and Clinicaltrials.gov databases until 2 April 2024 and only included randomized controlled trials. Outcomes included changes in UPDRS-III/MDS-UPDRS-III score, stride length, 10-meter walk test (10MWT), timed up-and-go (TUG) test, balance scale scores and quality-of-life (QoL) scores. Results were reported as mean differences (MD) or standardized mean differences (SMD), with 95% credible intervals (95% CrI).

Results

Fifty-one randomized controlled trials with 2095 patients were included. For UPDRS (motor outcome), all interventions had similar efficacies. VR intervention was the most effective in improving TUG compared with control (MD: −4.36, 95% CrI: −8.57, −0.35), outperforming robotic, exercise, and proprioceptive interventions. Proprioceptive intervention significantly improved stride length compared to control intervention (MD: 0.11 m, 95% CrI: 0.03, 0.19), outperforming VR, robotic and exercise interventions. Virtual reality improved balance scale scores significantly compared to exercise intervention (SMD: 0.75, 95% CrI: 0.12, 1.39) and control intervention (SMD: 1.42, 95% CrI: 0.06, 2.77). Virtual reality intervention significantly improved QoL scores compared to control intervention (SMD: −0.95, 95% CrI: −1.43, −0.52), outperforming Internet-based interventions.

Interpretation

VR-based and proprioceptive interventions were the most promising interventions, consistently ranking as the top treatment choices for most outcomes. Their use in clinical practice could be helpful in managing motor symptoms and QoL in PD.

目的:基于新技术的干预措施有望改善帕金森病(PD)患者的运动症状和步态。有前景的治疗方法包括虚拟现实(VR)训练、机器人辅助和生物反馈。这些疗法的效果尚不明确,因此我们进行了一项贝叶斯网络荟萃分析:我们检索了 Medline、Embase、Cochrane CENTRAL 和 Clinicaltrials.gov 数据库,直至 2024 年 4 月 2 日,只纳入了随机对照试验。研究结果包括UPDRS-III/MDS-UPDRS-III评分、步幅、10米步行测试(10MWT)、定时起立行走(TUG)测试、平衡量表评分和生活质量(QoL)评分的变化。结果以平均差(MD)或标准化平均差(SMD)以及 95% 可信区间(95% CrI)报告:结果:共纳入51项随机对照试验,2095名患者。就UPDRS(运动结果)而言,所有干预措施的疗效相似。与对照组相比,VR干预在改善TUG方面最为有效(MD:-4.36,95% CrI:-8.57,-0.35),优于机器人、运动和本体感觉干预。与对照组干预相比,本体感觉干预明显改善了步长(MD:0.11 米,95% CrI:0.03,0.19),优于虚拟现实、机器人和运动干预。与运动干预(SMD:0.75,95% CrI:0.12,1.39)和对照干预(SMD:1.42,95% CrI:0.06,2.77)相比,虚拟现实显著改善了平衡量表评分。与对照干预相比,虚拟现实干预能明显改善 QoL 评分(SMD:-0.95,95% CrI:-1.43,-0.52),优于基于互联网的干预:基于虚拟现实的干预和本体感觉干预是最有前景的干预措施,在大多数结果中一直是治疗的首选。在临床实践中使用这些干预措施有助于控制帕金森病患者的运动症状和生活质量。
{"title":"Innovative technology-based interventions in Parkinson's disease: A systematic review and meta-analysis","authors":"Chun En Yau,&nbsp;Eric Chi Kiat Ho,&nbsp;Natasha Yixuan Ong,&nbsp;Clifton Joon Keong Loh,&nbsp;Aaron Shengting Mai,&nbsp;Eng-King Tan","doi":"10.1002/acn3.52160","DOIUrl":"10.1002/acn3.52160","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Novel technology-based interventions have the potential to improve motor symptoms and gait in Parkinson's disease (PD). Promising treatments include virtual-reality (VR) training, robotic assistance, and biofeedback. Their effectiveness remains unclear, and thus, we conducted a Bayesian network meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched the Medline, Embase, Cochrane CENTRAL, and Clinicaltrials.gov databases until 2 April 2024 and only included randomized controlled trials. Outcomes included changes in UPDRS-III/MDS-UPDRS-III score, stride length, 10-meter walk test (10MWT), timed up-and-go (TUG) test, balance scale scores and quality-of-life (QoL) scores. Results were reported as mean differences (MD) or standardized mean differences (SMD), with 95% credible intervals (95% CrI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-one randomized controlled trials with 2095 patients were included. For UPDRS (motor outcome), all interventions had similar efficacies. VR intervention was the most effective in improving TUG compared with control (MD: −4.36, 95% CrI: −8.57, −0.35), outperforming robotic, exercise, and proprioceptive interventions. Proprioceptive intervention significantly improved stride length compared to control intervention (MD: 0.11 m, 95% CrI: 0.03, 0.19), outperforming VR, robotic and exercise interventions. Virtual reality improved balance scale scores significantly compared to exercise intervention (SMD: 0.75, 95% CrI: 0.12, 1.39) and control intervention (SMD: 1.42, 95% CrI: 0.06, 2.77). Virtual reality intervention significantly improved QoL scores compared to control intervention (SMD: −0.95, 95% CrI: −1.43, −0.52), outperforming Internet-based interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>VR-based and proprioceptive interventions were the most promising interventions, consistently ranking as the top treatment choices for most outcomes. Their use in clinical practice could be helpful in managing motor symptoms and QoL in PD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52160","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebellar transcranial magnetic stimulation improves motor function in Parkinson's disease 小脑经颅磁刺激可改善帕金森病患者的运动功能。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-05 DOI: 10.1002/acn3.52183
Marcus Grobe-Einsler, Viktoria Baljasnikowa, Aline Faikus, Tamara Schaprian, Oliver Kaut

Objective

To determine whether an accelerated protocol of 48 Hz cerebellar repetitive transcranial magnetic stimulation results in improved motor function in individuals with Parkinson's disease.

Methods

In this double-blind randomized sham-controlled study, 35 individuals with Parkinson's disease and stable medical treatment were randomized to either sham or verum transcranial magnetic stimulation. The stimulation was applied bilaterally and medial over the cerebellum and comprised a novel accelerated protocol encompassing two sessions per day on 5 consecutive days. Patients were assessed at baseline, on day 5 after the last stimulation and 1 month post intervention. Measurements included dynamic posturography, UPDRS III, 8-Meter walk test, and Timed Up and Go test.

Results

The accelerated protocol was safe and feasible in an outpatient setting. Patients in the verum group showed significant improvement (p < 0.001) of motor symptoms as measured in the UPDRS III. Improvement was mainly carried by the domains rigor, bradykinesia, and gait and persisted after 1 month (p = 0.009), whereas tremor remained unchanged.

Interpretation

The effect of a high-dose transcranial magnetic stimulation in patients with Parkinson's disease is encouraging and comparable to other studies using much longer stimulation protocols. This short-term intervention of 5 days facilitates the future application in an outpatient setting. Reduction in hospitalization rates directly benefits patients with motor impairment.

目的:确定 48 赫兹小脑重复经颅磁刺激加速方案是否能改善帕金森病患者的运动功能:确定 48 赫兹小脑重复经颅磁刺激加速方案是否能改善帕金森病患者的运动功能:在这项双盲随机假对照研究中,35 名接受过稳定治疗的帕金森病患者被随机分配接受假或 verum 经颅磁刺激。刺激在双侧小脑内侧进行,采用新的加速方案,每天两次,连续进行5天。患者分别在基线、最后一次刺激后第 5 天和干预后 1 个月接受评估。测量项目包括动态脑电图、UPDRS III、8米步行测试和定时起立行走测试:加速方案在门诊环境中安全可行。verum组患者的病情有了明显改善(p 解释:高剂量经颅磁刺激治疗的效果明显:对帕金森病患者进行大剂量经颅磁刺激的效果令人鼓舞,可与其他使用更长时间刺激方案的研究相媲美。这种为期 5 天的短期干预有利于今后在门诊环境中应用。住院率的降低可使运动障碍患者直接受益。
{"title":"Cerebellar transcranial magnetic stimulation improves motor function in Parkinson's disease","authors":"Marcus Grobe-Einsler,&nbsp;Viktoria Baljasnikowa,&nbsp;Aline Faikus,&nbsp;Tamara Schaprian,&nbsp;Oliver Kaut","doi":"10.1002/acn3.52183","DOIUrl":"10.1002/acn3.52183","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine whether an accelerated protocol of 48 Hz cerebellar repetitive transcranial magnetic stimulation results in improved motor function in individuals with Parkinson's disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this double-blind randomized sham-controlled study, 35 individuals with Parkinson's disease and stable medical treatment were randomized to either sham or verum transcranial magnetic stimulation. The stimulation was applied bilaterally and medial over the cerebellum and comprised a novel accelerated protocol encompassing two sessions per day on 5 consecutive days. Patients were assessed at baseline, on day 5 after the last stimulation and 1 month post intervention. Measurements included dynamic posturography, UPDRS III, 8-Meter walk test, and Timed Up and Go test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The accelerated protocol was safe and feasible in an outpatient setting. Patients in the verum group showed significant improvement (<i>p</i> &lt; 0.001) of motor symptoms as measured in the UPDRS III. Improvement was mainly carried by the domains rigor, bradykinesia, and gait and persisted after 1 month (<i>p</i> = 0.009), whereas tremor remained unchanged.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The effect of a high-dose transcranial magnetic stimulation in patients with Parkinson's disease is encouraging and comparable to other studies using much longer stimulation protocols. This short-term intervention of 5 days facilitates the future application in an outpatient setting. Reduction in hospitalization rates directly benefits patients with motor impairment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis 血清胶质纤维酸性蛋白可预测多发性硬化症的病情发展。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-05 DOI: 10.1002/acn3.52187
Evan Madill, Brian C. Healy, Negar Molazadeh, Mariann Polgar-Turcsanyi, Bonnie I. Glanz, Howard L. Weiner, Tanuja Chitnis

Objective

Glial fibrillary acidic protein (GFAP) is expressed in astrocytes and may be a useful marker of non-active progressive multiple sclerosis (MS). We evaluate serum GFAP (sGFAP) in a large cohort of MS patients to determine if it predicts progression independent of relapse activity (PIRA), future gait aid, and conversion to secondary progressive disease (SPMS).

Methods

Adults with clinically isolated syndrome or any subtype of MS who were listed in the Brigham MS Center Research Database and had at least one sGFAP result were included. All clinic visits following first sample were analyzed for PIRA, future gait aid, and conversion to SPMS. Future cognitive dysfunction and fatigue were evaluated as secondary outcomes.

Results

In total, 741 patients were included (average age: 42.3, average disease duration: 3.7 years, median EDSS: 2, and median follow-up duration: 10.0 years). Of 643 patients (86.8%) without progressive disease at baseline, 15.9% developed SPMS. Among all 741, 50.5% had PIRA and 18.6% developed a gait aid requirement. sGFAP level predicted PIRA, future gait aid, and conversion to SPMS in univariable models (p < 0.001, <0.001, and 0.002). sGFAP remained predictive for PIRA and future gait aid in multivariable models in those younger than 50 (p = 0.048, 0.003). Change in sGFAP level over time was not predictive. There was no association between sGFAP and future fatigue or cognitive dysfunction.

Interpretation

sGFAP helps to predict PIRA, future gait aid, and conversion to SPMS in a large cohort of MS patients. Our data suggest that baseline levels may be more useful than the change over time.

目的:胶质纤维酸性蛋白(GFAP)在星形胶质细胞中表达,可能是非活动性进展型多发性硬化症(MS)的有用标记物。我们对一大群多发性硬化症患者的血清 GFAP(sGFAP)进行了评估,以确定它是否能预测独立于复发活动的进展(PIRA)、未来的步态辅助以及向继发性进展性疾病(SPMS)的转化:方法:纳入布里格姆多发性硬化症中心研究数据库中的临床孤立综合征或任何亚型多发性硬化症成人患者,他们至少有一项 sGFAP 结果。对首次采样后的所有门诊就诊情况进行分析,以了解 PIRA、未来步态辅助和转为 SPMS 的情况。未来认知功能障碍和疲劳作为次要结果进行评估:共纳入了 741 名患者(平均年龄:42.3 岁,平均病程:3.7 年,ED 中位数:3.7%):3.7年,EDSS中位数:2,随访时间中位数:10.0年):10.0年)。在基线时没有进展性疾病的 643 名患者(86.8%)中,15.9% 发展为 SPMS。在单变量模型中,sGFAP水平可预测PIRA、未来的步态辅助和转为SPMS(p 解释:sGFAP有助于预测PIRA、未来的步态辅助和转为SPMS。我们的数据表明,基线水平可能比随时间的变化更有用。
{"title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","authors":"Evan Madill,&nbsp;Brian C. Healy,&nbsp;Negar Molazadeh,&nbsp;Mariann Polgar-Turcsanyi,&nbsp;Bonnie I. Glanz,&nbsp;Howard L. Weiner,&nbsp;Tanuja Chitnis","doi":"10.1002/acn3.52187","DOIUrl":"10.1002/acn3.52187","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glial fibrillary acidic protein (GFAP) is expressed in astrocytes and may be a useful marker of non-active progressive multiple sclerosis (MS). We evaluate serum GFAP (sGFAP) in a large cohort of MS patients to determine if it predicts progression independent of relapse activity (PIRA), future gait aid, and conversion to secondary progressive disease (SPMS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adults with clinically isolated syndrome or any subtype of MS who were listed in the Brigham MS Center Research Database and had at least one sGFAP result were included. All clinic visits following first sample were analyzed for PIRA, future gait aid, and conversion to SPMS. Future cognitive dysfunction and fatigue were evaluated as secondary outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 741 patients were included (average age: 42.3, average disease duration: 3.7 years, median EDSS: 2, and median follow-up duration: 10.0 years). Of 643 patients (86.8%) without progressive disease at baseline, 15.9% developed SPMS. Among all 741, 50.5% had PIRA and 18.6% developed a gait aid requirement. sGFAP level predicted PIRA, future gait aid, and conversion to SPMS in univariable models (<i>p</i> &lt; 0.001, &lt;0.001, and 0.002). sGFAP remained predictive for PIRA and future gait aid in multivariable models in those younger than 50 (<i>p</i> = 0.048, 0.003). Change in sGFAP level over time was not predictive. There was no association between sGFAP and future fatigue or cognitive dysfunction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>sGFAP helps to predict PIRA, future gait aid, and conversion to SPMS in a large cohort of MS patients. Our data suggest that baseline levels may be more useful than the change over time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity B 细胞和水通道蛋白-4 抗体与神经脊髓炎视谱系障碍活动的关系。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-02 DOI: 10.1002/acn3.52171
Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, Kevin C. O'Connor, Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce A. C. Cree

This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.

这项伊维单抗治疗神经性脊髓炎视网膜频谱紊乱症(NMOSD)的随机安慰剂对照 N-MOmentum 研究(NCT02200770)的事后分析评估了循环 B 细胞亚群和水通道蛋白-4 免疫球蛋白 G (AQP4-lgG) 滴度与发作之间的关系。在接受安慰剂治疗的参与者中,CD20+和CD27+ B细胞计数从发作前到发作期间略有增加;浆细胞/浆细胞基因特征从基线到发作前(p = 0.016)以及从基线到发作期间(p = 0.009)均有所增加。接受伊匹单抗治疗后,B细胞亚群数量减少,且不随发作而增加。从基线到发病时,AQP4-IgG滴度的变化无差异。
{"title":"B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity","authors":"Jeffrey L. Bennett,&nbsp;Sean J. Pittock,&nbsp;Friedemann Paul,&nbsp;Ho Jin Kim,&nbsp;Sarosh R. Irani,&nbsp;Kevin C. O'Connor,&nbsp;Kristina R. Patterson,&nbsp;Michael A. Smith,&nbsp;Michele Gunsior,&nbsp;Nanette Mittereder,&nbsp;William A. Rees,&nbsp;Daniel Cimbora,&nbsp;Bruce A. C. Cree","doi":"10.1002/acn3.52171","DOIUrl":"10.1002/acn3.52171","url":null,"abstract":"<p>This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20<sup>+</sup> and CD27<sup>+</sup> B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (<i>p</i> = 0.016) and from baseline to attack (<i>p</i> = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.</p>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase 静脉注射脉冲甲基强的松龙对急性期神经脊髓炎视网膜病变的影响。
IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-02 DOI: 10.1002/acn3.52188
Shengnan Wang, Mengru Xue, Jianglong Wang, Rui Wu, Yanqing Shao, Ke Luo, Jiacheng Liu, Mingqin Zhu
<div> <section> <h3> Background</h3> <p>Neuromyelitis optica spectrum disorder (NMOSD) is an anti-aquaporin 4 (anti-AQP4) autoantibodies-mediated idiopathic inflammatory demyelinating disease of the central nervous system. While intravenous pulse methylprednisolone (IVMP) is the recommended initial treatment option for acute onset NMOSD, its therapeutic mechanism remains unclear. We hypothesized that IVMP would reduce the expression of pro-inflammatory factors and increase the resolution of inflammation in patients with NMOSD.</p> </section> <section> <h3> Methods</h3> <p>Mendelian randomization (MR) analysis was used to screen meaningful inflammatory and resolution factors for inclusion. Three MR methods with inverse variance weighting (IVW) were primarily used to identify positive results. Interleukin (IL)-10, IL-1β, IL-6, C-X-C motif chemokine ligand 12 (CXCL12), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were screened from 41 inflammatory factors, and resolvin D1 (RvD1), maresin 1 (MaR1), and lipoxin A4 (LXA4) were screened from 6 resolution markers for inclusion. Subsequently, 12 patients with NMOSD were enrolled and treated with IVMP. Serum levels of the aforementioned inflammatory and resolution markers were measured by enzyme-linked immunosorbent assay before and after IVMP treatment.</p> </section> <section> <h3> Results</h3> <p>High levels of TRAIL, CXCL12, and IL-1β were associated with an increased risk of NMOSD (TRAIL: odds ratio [OR], 1.582; 95% confidence interval [CI], 1.003–2.495; CXCL12: OR, 3.610; 95% CI, 1.011–12.889; IL-1β: OR, 4.500; 95% CI, 1.129–17.927). High levels of RvD1, MaR1, and LXA4 were associated with a reduced risk of NMOSD (RvD1: OR, 0.725; 95% CI, 0.538–0.976; MaR1: OR, 0.985; 95% CI, 0.970–0.999; LXA4: OR, 0.849; 95% CI, 0.727–0.993). Among patients with NMOSD, serum levels of IL-6, CXCL12, and TRAIL significantly decreased following IVMP treatment, compared with pretreatment levels, while levels of IL-1β, LXA4, and MaR1 significantly increased after IVMP treatment (<i>p</i> < 0.05). A significant positive correlation was observed between CXCL12 levels and Expanded Disability Status Scale (EDSS) scores (<i>r</i> = 0.451, <i>p</i> < 0.05).</p> </section> <section> <h3> Conclusion</h3> <p>Several systemic inflammatory regulators associated with the pathogenesis of NMOSD were identified. The protective roles of LXA4 and MaR1 may be indispensable components of glucocorticoid treatment. Therefore, the use of resolution markers may be a potential strategy for improving central nervous sy
背景:神经脊髓炎视网膜谱系障碍(NMOSD)是一种由抗喹波蛋白4(anti-AQP4)自身抗体介导的中枢神经系统特发性炎症性脱髓鞘疾病。虽然静脉脉冲甲基强的松龙(IVMP)是急性发作的 NMOSD 的推荐初始治疗方案,但其治疗机制仍不清楚。我们假设 IVMP 将减少促炎因子的表达,并增加 NMOSD 患者炎症的缓解:方法:采用孟德尔随机化(MR)分析筛选有意义的炎症和缓解因子。主要使用三种带有反方差加权(IVW)的 MR 方法来确定阳性结果。从 41 个炎症因子中筛选出白细胞介素 (IL)-10、IL-1β、IL-6、C-X-C 矩阵趋化因子配体 12 (CXCL12)、肿瘤坏死因子相关凋亡诱导配体 (TRAIL),从 6 个分辨率标记物中筛选出 resolvin D1 (RvD1)、maresin 1 (MaR1) 和 lipoxin A4 (LXA4)。随后,12 名 NMOSD 患者入选并接受了 IVMP 治疗。通过酶联免疫吸附试验测定了IVMP治疗前后血清中上述炎症标志物和溶解标志物的水平:结果:高水平的 TRAIL、CXCL12 和 IL-1β 与罹患 NMOSD 的风险增加相关(TRAIL:比值比 [OR],1.582;95% 置信区间 [CI],1.003-2.495;CXCL12:OR,3.610;95% CI,1.011-12.889;IL-1β:OR,4.500;95% CI,1.129-17.927)。高水平的 RvD1、MaR1 和 LXA4 与罹患 NMOSD 的风险降低有关(RvD1:OR,0.725;95% CI,0.538-0.976;MaR1:OR,0.985;95% CI,0.970-0.999;LXA4:OR,0.849;95% CI,0.727-0.993)。在 NMOSD 患者中,与治疗前相比,IL-6、CXCL12 和 TRAIL 的血清水平在 IVMP 治疗后显著降低,而 IL-1β、LXA4 和 MaR1 的水平在 IVMP 治疗后显著升高(p 结论:IL-6、CXCL12 和 TRAIL 的水平在 IVMP 治疗后显著降低,而 IL-1β、LXA4 和 MaR1 的水平在 IVMP 治疗后显著升高:研究发现了与 NMOSD 发病机制相关的几种全身炎症调节因子。LXA4 和 MaR1 的保护作用可能是糖皮质激素治疗不可或缺的组成部分。因此,使用分辨率标记物可能是改善 NMOSD 患者中枢神经系统损伤的潜在策略。
{"title":"Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase","authors":"Shengnan Wang,&nbsp;Mengru Xue,&nbsp;Jianglong Wang,&nbsp;Rui Wu,&nbsp;Yanqing Shao,&nbsp;Ke Luo,&nbsp;Jiacheng Liu,&nbsp;Mingqin Zhu","doi":"10.1002/acn3.52188","DOIUrl":"10.1002/acn3.52188","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Neuromyelitis optica spectrum disorder (NMOSD) is an anti-aquaporin 4 (anti-AQP4) autoantibodies-mediated idiopathic inflammatory demyelinating disease of the central nervous system. While intravenous pulse methylprednisolone (IVMP) is the recommended initial treatment option for acute onset NMOSD, its therapeutic mechanism remains unclear. We hypothesized that IVMP would reduce the expression of pro-inflammatory factors and increase the resolution of inflammation in patients with NMOSD.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Mendelian randomization (MR) analysis was used to screen meaningful inflammatory and resolution factors for inclusion. Three MR methods with inverse variance weighting (IVW) were primarily used to identify positive results. Interleukin (IL)-10, IL-1β, IL-6, C-X-C motif chemokine ligand 12 (CXCL12), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were screened from 41 inflammatory factors, and resolvin D1 (RvD1), maresin 1 (MaR1), and lipoxin A4 (LXA4) were screened from 6 resolution markers for inclusion. Subsequently, 12 patients with NMOSD were enrolled and treated with IVMP. Serum levels of the aforementioned inflammatory and resolution markers were measured by enzyme-linked immunosorbent assay before and after IVMP treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;High levels of TRAIL, CXCL12, and IL-1β were associated with an increased risk of NMOSD (TRAIL: odds ratio [OR], 1.582; 95% confidence interval [CI], 1.003–2.495; CXCL12: OR, 3.610; 95% CI, 1.011–12.889; IL-1β: OR, 4.500; 95% CI, 1.129–17.927). High levels of RvD1, MaR1, and LXA4 were associated with a reduced risk of NMOSD (RvD1: OR, 0.725; 95% CI, 0.538–0.976; MaR1: OR, 0.985; 95% CI, 0.970–0.999; LXA4: OR, 0.849; 95% CI, 0.727–0.993). Among patients with NMOSD, serum levels of IL-6, CXCL12, and TRAIL significantly decreased following IVMP treatment, compared with pretreatment levels, while levels of IL-1β, LXA4, and MaR1 significantly increased after IVMP treatment (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). A significant positive correlation was observed between CXCL12 levels and Expanded Disability Status Scale (EDSS) scores (&lt;i&gt;r&lt;/i&gt; = 0.451, &lt;i&gt;p&lt;/i&gt; &lt; 0.05).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Several systemic inflammatory regulators associated with the pathogenesis of NMOSD were identified. The protective roles of LXA4 and MaR1 may be indispensable components of glucocorticoid treatment. Therefore, the use of resolution markers may be a potential strategy for improving central nervous sy","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Clinical and Translational Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1